A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer

A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer

Novel biomarkers are urgently needed to improve the prediction of clinical outcomes and guide personalized treatment for prostate cancer (PCa) patients. However, the role of N6-methyladenosine (m6A) modifications in PCa initiation and progression remains largely elusive. In our study, we collected b...

Full description

Bibliographic Details
Main Authors: Jianming Lu, Jiahong Chen, Zhuoyuan Lin, Qinwei Liu, Chuanfan Zhong, Zhouda Cai, Zhenyu Jia, Weide Zhong, Yingke Liang, Chao Cai
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:Translational Oncology
Subjects:
Prostate cancer
N6-methyladenosine modified mRNA
Prognostic signature
Biochemical recurrence
Androgen receptor signaling inhibitor
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523323000566

Internet

http://www.sciencedirect.com/science/article/pii/S1936523323000566

Similar Items